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EgyptAbstract Background: Trans-catheter Aortic Valve Implantation (TAVI) offers a less invasive
modality to manage aortic stenosis (AS) especially in high risk patients. It was not available in
Egypt until the end of 2011.
Aim: The aim of this study is to report immediate and one year follow up results of ﬁrst TAVI
implantations in Egyptian patients.
Patients and methods: Ten patients with severe symptomatic AS underwent TAVI implantation
using Edwards SAPIEN and SAPIEN XT valves.
Results: The mean age was 78.6 ± 4.6 years and 5 (50%) were males. The mean Logistic EuroSCORE
andEuroSCORE IIwere 21.9 ± 11.5%and12.6 ± 7.2%, respectively. Procedural successwas achieved
in all (100%) patients using SAPIEN (n= 8) and SAPIEN XT (n= 2) valves. Almost all (n= 9)
patients underwent a trans-femoral approach and percutaneous closure devices were used in the last 2
patients. Post procedural NYHAgrade (1.3 ± 0.3), aortic valve area (2.0 ± 0.1 cm2) andmean pressure
gradient (14.1 ± 2.7 mmHg) were nearly maintained all over the one-year-follow-up period.
Conclusion: TAVI provides a safe and effective alternative to the surgicalAVR in high risk patients with
severe symptomatic AS. Financial issues, however, limits its application in developing countries.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
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Trans-catheter Aortic Valve Implantation (TAVI) is a great
milestone in the rapidly evolving ﬁeld of cardiovascular inter-
ventions especially as it targets aortic stenosis (AS), the com-
monest valve disease in adults.1 Although surgical aortic
valve replacement (AVR) had gained solid evidence and wide-
spread use, one third of the patients are declined due to pro-
hibitively high operative risk.2 This proportion is expected to
further increase with the aging population and improving med-
ical care (Figs. 1 and 2).
These issues raised the need for a less invasive modality and
led to the introduction of the ﬁrst percutaneous aortic valve by
Cribier et al. in 2002.3 By 2007, two devices, the Edwards SAP-
IEN (Edwards Lifesciences LLC, Irvine, CA, USA) and
CoreValve ReValving System (Medtronic LLC, Irvine, CA,
USA) received the CE mark approval. This was followed by
progressive technical support and scientiﬁc evidence.
It was not before the end of 2011 when the ﬁrst device,
Edward SAPIEN, was approved in Egypt. Having the
chance to be the ﬁrst team to perform TAVI in Egypt, we here
report our early data which represents the premier Egyptian
experience.Figure 1 Edwards SAPIEN (A)
Figure 2 The RetroFlex-3 (A), NovaFlex2. Methods
2.1. The team
Our team consists of three cardiologists, a cardiothoracic sur-
geon, a vascular surgeon, an anesthesiologist and an echocar-
diographer. The cardiologists underwent training in a
specialized training center in Neon, Switzerland. The ﬁrst 5
cases were proctored; thereafter we were declared an approved
center for independent Edwards SAPIEN prosthesis
implantation.
2.2. Patients
Between December 2011 and February 2013, 40 patients with
severe (aortic valve area < 0.8 cm2 and mean pressure gradi-
ent > 40 mmHg) symptomatic AS were screened as candidates
for TAVI. Contraindications included dominant aortic regur-
gitation, bicuspid aortic valve, unsuitable annular size or land-
ing zone. EuroSCORE system4,5 guided the further selection of
patients according to surgical risk; main determinants were
age, gender, comorbidities and cardiac-related factors.and SAPIEN XT (B) valves.
(B) and Ascendra (C) delivery systems.
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cardiography to assess disease severity, annular size and land-
ing zone suitability. Coronary, aortic and ilio-femoral
angiography and computed tomography were used to assess
the respective arterial tree and choose the preferred route.
2.3. Devices
Patients received Edwards SAPIEN and SAPIEN XT
valves. Both consist of a trileaﬂet bovine pericardial valve and
a balloon-expandable, stainless-steel support frame. Two sizes
are currently available: 23 and 26 mm expanded diameter. They
were used for 18–22 mm and 21–25 mm annulus diameters,
respectively. The prosthetic stent valve is mechanically crimped
onto a balloon catheter immediately before implantation.
Edwards SAPIEN valve was implanted using the Retro-
Flex-II delivery system for transfemoral procedures and the
Ascendra transapical catheter for transapical procedures. Later
cases utilized Edwards SAPIEN XT valve and the Novaﬂex
(Edwards Lifesciences, Irvine, California) delivery system.
2.4. The procedure
The procedures were performed in a catheterization laboratory
under strict sterile conditions. Patients were premedicated with
clopidogrel and aspirin, received prophylactic antibiotics imme-
diately prior to and unfractionated heparin (100 IU/kg) during
the procedure. All cases were done under general anesthesia to
facilitate continuous TEE monitoring. Transfemoral approach
was used unless precluded by extensive ileo-femoral calciﬁcation.
Surgical femoral arteriotomy (except in later cases) was
done to facilitate the passage of the large caliber catheters
(24 and 22 French for the 26 and 23 mm SAPIEN valve and
19 and 18 French for the 26 and 23 mm SAPIEN XT valve,
respectively). An Amplatzer extra-stiff guide wire was
passed over the aortic valve. A 20–22 mm balloon was used
to pre-dilate the aortic valve under rapid ventricular pacing.
The valve was then positioned ﬂuoroscopically and deployed
with balloon inﬂation under rapid ventricular pacing. Immedi-
ate success was assessed with supra aortic contrast injection
and TEE. The puncture site in the groin was closed surgically
in early cases but later percutaneous closure was performed
(Proglide, Abbott Vascular, Chicago, IL, USA).
The technique for the SAPIEN XT implantation is simi-
lar except that the valve is mounted on the delivery catheter,
behind the balloon. Once exited from the insertion sheath into
the abdominal aorta, the balloon is pulled back into the
crimped valve and clicks into place. The mounted valve is then
advanced further up the aorta.
For the transapical approach, a left mini-thoracotomy was
made exposing the left ventricular apex. After puncture of the
left ventricular apex, the rest of the procedure is largely the
same as for the transfemoral approach, except that the valve
is mounted in the opposite orientation on the balloon catheter.
After the procedure, the patients received clopidogrel for
6 months and aspirin indeﬁnitely.
2.5. Study end-points
After the procedure, patients were assessed for complications,
procedural success rate, 30-day mortality and New York HeartAssociation functional status. As proposed by Valve Academic
Research Consortium6, major complications included stroke,
major vascular complications requiring acute intervention or
blood transfusion, conduction abnormalities requiring perma-
nent pacing and renal failure requiring dialysis.
An echocardiogram was performed prior to discharge,
1 month, 6 months and 1 year post procedure.
2.6. Statistical analysis
All demographic, clinical, and technical data were collected
using the ‘‘Data Collection Form’’ and entered into a comput-
erized database. Data obtained from all patients were statisti-
cally analyzed on a PC using commercially available statistical
analysis software (Statistica version 7.0).
Continuous variables were compared using analysis of
variance (ANOVA) for repeated measures. The Fisher’s exact
chi-square test with was used for comparison of categoric vari-
ables. A P-value < 0.05 was considered statistically signiﬁcant.
All data were expressed as mean ± standard deviation
(mean ± SD) or number (%) as appropriate.3. Results
3.1. Baseline characteristics
Ten patients who were included in this study completed the
one-year follow-up. The mean age was 78.6 ± 4.6 years and
5 (50%) were males. The mean Logistic EuroSCORE and
EuroSCORE II were 21.9 ± 11.5% and 12.6 ± 7.2%, respec-
tively (Table 1).
3.2. Procedural outcomes and complications
Procedural success was achieved in all (100%) patients. Almost
all (n= 9) patients underwent a trans-femoral approach ex-
cept the 3rd patient who showed extensive iliac calciﬁcation
indicating trans-apical approach. The patients received SAP-
IEN (n= 8) and SAPIEN XT (n= 2) valves. Percutane-
ous closure devices (Proglide) were used in the last 2
patients. Deviations from the smooth classic procedure oc-
curred in some patients (Table 2).
Patient 2 had a baseline conduction abnormality in the
form of ﬁrst degree heart block and left anterior hemiblock.
After valve deployment he developed complete heart block
necessitating permanent pacing.
Patient 5 showed difﬁculty in passing the valve into the aor-
tic valve despite several attempts. It was not until we developed
a new technique that valve passage was successful; the valve
was advanced while simultaneously deﬂating the balloon ‘‘slid-
ing-over-deﬂating-buddy-balloon technique’’.
Patients 6 and 8 underwent concomitant coronary revascu-
larization and patient 10 showed an interrupted inferior vena
cava so the wire was passed through the hemiazygous vein.
3.3. Follow-up measurements
Echocardiographic assessment was done immediately, 24 h,
6 months and 12 months after implantation. Neither patients
showed any change regarding valve area, mean pressure
Table 1 Baseline clinical characteristics.
Variable
Age (years) 78.6 ± 4.6
Male gender 5 (50%)
Body mass index (kg/m2) 29.4 ± 3.7
Past and current smokers 3 (30%)
Diabetes 7 (70%)
Hypertension 6 (60%)
Coronary artery disease 4 (40%)
Stroke/TIA 0 (0%)
Syncope 3 (30%)
Angina at rest 5 (50%)
Previous MI 3 (30%)
Previous PCI 4 (40%)
Previous CABG 3 (30%)
Previous Valvuloplasty 0 (0%)
Peripheral vascular disease 2 (20%)
Porcelain aorta 0 (0%)
Chronic lung disease 3 (30%)
Chronic kidney disease 3 (30%)
Pulmonary hypertension 4 (40%)
NYHA class 3.5 ± 0.5
Logistic EuroSCORE (%) 21.9 ± 11.5
EuroSCORE II (%) 12.6 ± 7.2
Values are presented as mean ± SD and number (percentage). TIA:
Transient ischemic attacks, MI: Myocardial infarction, PCI: Per-
cutaneous coronary intervention, CABG: coronary artery bypass
graft, EuroSCORE: European System for Cardiac Operative Risk
Evaluation, NYHA: New York Heart Association.
Table 2 Procedural parameters and outcomes.
Variable
Successful valvuloplasty 10 (100%)
Successful valve implantation 10 (100%)
Implanted valve type
SAPIEN 8 (80%)
SAPIEN XT 2 (20%)
Implanted valve size
23 mm 4 (40%)








Right femoral access 5 (50%)
Left femoral access 4 (40%)
Surgical closure 8 (80%)
Percutaneous puncture 2 (20%)
Aortic Regurgitation > grade 1 0 (0%)
Paravalvular leak > mild 0 (0%)
Valve embolization 0 (0%)
Valve-in-valve implantation 0 (0%)
Coronary obstruction 0 (0%)
Myocardial infarction 0 (0%)
Left ventricular perforation 0 (0%)
Permanent pacemaker 1 (10%)
Vascular complications in transfemoral approach 0 (0%)
TIA 1 (10%)
Procedure-related death 0 (0%)
NYHA grade 1.3 ± 0.3
LOS (days) 8 ± 6
Values are presented as mean ± SD and number (percentage).
NYHA: New York Heart Association, LOS: Length of stay.
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6 months postprocedure, patient 7 developed severe chest
infection followed by infective endocarditis of the prosthetic
valve. She was admitted to our hospital and received extensive
antibiotic therapy. Unfortunately she did not improve and
died 1 month later (Table 3).
4. Discussion
This premier Egyptian experience with TAVI reproduces the
results reported by other well-known centers.7–10 With good
team training, proper patient selection and experienced proc-
tor supervision we reached a 100% success rate with excellent
procedural and clinical outcomes despite being in the start of
our learning curve.
Results proved the safety of the procedure compared to sur-
gical AVR in a population with logistic EuroSCORE predicted
mortality of 21.9 ± 11.5%.11 No procedure-related deaths oc-
curred and the only fatality, patient 7, occurred 5 months later
due to an acquired cause (infective endocarditis). Aside from
the permanent pacemaker implantation in patient 2, no other
major complications were encountered and all procedural dif-
ﬁculties were manageable. Hospital LOS was 8 days as a mean.
Even the remarkably high LOS of patient 5, 24 days, was due
to ascitic ﬂuid oozing from the femoral incision site and not re-
lated to any vascular complications.
All patients experienced a signiﬁcant early symptomatic
improvement (NYHA 1.3 ± 0.3) which was maintained all
over the 1 year follow up period together with the good echo-
cardiographic results (AVA 2.0 ± 0.1 cm2, MPG
14.1 ± 2.7 mmHg).The PARTNER trial is the most important clinical trial of
the SAPIEN valve. It was designed as a non-inferiority study
where 699 high-risk patients with severe AS were randomly as-
signed to undergo either TAVI or surgical replacement. The
rates of death from any cause were 3.4% in the transcatheter
group and 6.5% in the surgical group at 30 days (P= 0.07)
and 24.2% and 26.8%, respectively, at 1 year (P= 0.44).
The rates of major stroke were 3.8% in the transcatheter group
and 2.1% in the surgical group at 30 days (P= 0.20) and
5.1% and 2.4%, respectively, at 1 year (P= 0.07). At 30 days,
major vascular complications were signiﬁcantly more frequent
with transcatheter replacement (11.0% vs. 3.2%, P< 0.001);
adverse events that were more frequent after surgical replace-
ment included major bleeding (9.3% vs. 19.5%, P< 0.001)
and new-onset atrial ﬁbrillation (8.6% vs. 16.0%,
P= 0.006). More patients undergoing transcatheter replace-
ment had an improvement in symptoms at 30 days, but by
1 year, there was no signiﬁcant between-group difference. They
concluded that, in high-risk patients with severe aortic steno-
sis, transcatheter and surgical procedures for aortic-valve
replacement were associated with similar rates of survival at
1 year, although there were important differences in periproce-
dural risks.12
The PARTNER II Trial which is currently recruiting par-
ticipants is targeting a new population, those with intermediate
Table 3 Survival, symptomatic and echocardiographic data.
Baseline Postprocedure One-year follow-up
Survival 10 10 (100%) 9 (90%)
Symptoms (NYHA) 3.5 ± 0.5 1.3 ± 0.3 1.3 ± 0.3
Echocardiography
AVA (cm2) 0.8 ± 0.1 2.0 ± 0.1 2.0 ± 0.1
MPG (mmHg) 64.8 ± 17.8 14.1 ± 2.7 14.6 ± 2.5
Annulus (mm) 21.4 ± 1.9 NA NA
EF (%) 40.7 ± 16.5 49.9 ± 11.4 50.9 ± 10.4
AR Grade 0.7 ± 0.6 0.3 ± 0.3 0.3 ± 0.3
MR Grade 1.0 ± 0.9 0.8 ± 0.6 0.8 ± 0.6
Values are presented as mean ± SD and number (percentage). AVA: aortic valve area, EF: left ventricular ejection fraction, MPG: mean aortic
valve pressure gradient, MR/AR grade: grade of mitral/aortic valve insufﬁciency.
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for aortic valve surgery (Cohort B – inoperable). This trial is
expected to broaden the indications of TAVI but it will not
be completed until May 2018.13
Side to side with future expected broader indications; tech-
nological improvements will further increase the suitability
and decrease complication rates of TAVI. New valve sizes will
expand the suitable AV annulus sizes and smaller arterial
sheaths will decrease vascular complications probably nullify-
ing the need for the transapical approach. However, the lim-
ited ﬁnancial resources available in a developing country like
Egypt are still the main obstacle against widespread
application.
5. Conclusion
TAVI provides a safe and effective alternative to the surgical
AVR in high risk patients with severe symptomatic AS.14 With
technological advances, indications are continuously expand-
ing to cover an ever growing patient population. Financial is-
sues, however, limits its application in developing countries.
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